PMID- 29430171
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1177-5475 (Print)
IS  - 1177-5491 (Electronic)
IS  - 1177-5475 (Linking)
VI  - 12
DP  - 2018
TI  - Correlation between HLA haplotypes and the development of antidrug antibodies in 
      a cohort of patients with rheumatic diseases.
PG  - 37-41
LID - 10.2147/BTT.S145941 [doi]
AB  - INTRODUCTION: The aim of this study was to investigate the correlation between 
      human leukocyte antigen (HLA) haplotypes and the development of antidrug 
      antibodies (ADAs) in a cohort of patients with rheumatic diseases. PATIENTS AND 
      METHODS: We evaluated the presence of ADAs in 248 patients with inflammatory 
      rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients 
      were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with 
      ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with 
      adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept 
      (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 
      25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; 
      three with RA, seven with AS, nine with PsA). Serum drug and ADA levels were 
      determined using Lisa-Tracker Duo, the ADA-positive samples underwent an 
      inhibition test, and the true-positive samples underwent genetic HLA typing. To 
      have a homogeneous control population, we also performed genetic HLA typing of 11 
      ADA-negative patients. RESULTS: After inhibition test, the frequency of ADAs was 
      2/26 patients treated with IFX (7.69%), 4/83 treated with ADA (4.81%), 0/88 
      treated with ETA (0%), 4/32 treated with CERT (12.5%), and 1/19 treated with GOL 
      (5.26%). The frequency of HLA alleles in the examined patients was HLA-DRbeta-11 
      0.636, HLA-DQ-03 0.636, and HLA-DQ-05 0.727. The estimated relative risks between 
      the ADA-positive patients and the ADA-negative patients were HLA-DRbeta-11 2.528 
      (95% CI 0.336-19.036), HLA-DQ-03 1.750 (95% CI 0.289-10.581), and HLA-DQ-05 2.424 
      (95% CI 0.308-15.449). CONCLUSION: This is the first study that shows an 
      association between HLA and genetic factors associated with the occurrence of 
      ADAs in patients with rheumatic diseases, but the number of samples is too small 
      to draw any definite conclusion.
FAU - Benucci, Maurizio
AU  - Benucci M
AD  - Rheumatology Unit.
FAU - Damiani, Arianna
AU  - Damiani A
AD  - Rheumatology Unit.
FAU - Li Gobbi, Francesca
AU  - Li Gobbi F
AD  - Rheumatology Unit.
FAU - Bandinelli, Francesca
AU  - Bandinelli F
AD  - Rheumatology Unit.
FAU - Infantino, Maria
AU  - Infantino M
AD  - Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. 
      Giovanni di Dio, Florence, Italy.
FAU - Grossi, Valentina
AU  - Grossi V
AD  - Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. 
      Giovanni di Dio, Florence, Italy.
FAU - Manfredi, Mariangela
AU  - Manfredi M
AD  - Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. 
      Giovanni di Dio, Florence, Italy.
FAU - Noguier, Guillaume
AU  - Noguier G
AD  - Theradiag, Croissy Beaubourg, France.
FAU - Meacci, Francesca
AU  - Meacci F
AD  - Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. 
      Giovanni di Dio, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180131
PL  - New Zealand
TA  - Biologics
JT  - Biologics : targets & therapy
JID - 101321511
PMC - PMC5797458
OTO - NOTNLM
OT  - HLA haplotypes
OT  - antidrug antibodies
OT  - rheumatic diseases
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/02/13 06:00
MHDA- 2018/02/13 06:01
PMCR- 2018/01/31
CRDT- 2018/02/13 06:00
PHST- 2018/02/13 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/02/13 06:01 [medline]
PHST- 2018/01/31 00:00 [pmc-release]
AID - btt-12-037 [pii]
AID - 10.2147/BTT.S145941 [doi]
PST - epublish
SO  - Biologics. 2018 Jan 31;12:37-41. doi: 10.2147/BTT.S145941. eCollection 2018.